Maximizing the use of batch production of 18F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting.
Mariam S AboianRamon BarajasJulia ShatalovVahid RavanfarEmma BahroosElizabeth TongJennie W TaylorN Oberheim BushPatricia SneedYoungho SeoSoonmee ChaMiguel Hernandez-PampaloniPublished in: Neuro-oncology practice (2020)
Amino acid PET tracers have been shown to play a critical role in the characterization of brain tumors but their adaptation to clinical practice has been limited because of the high cost of PET. Scheduling patient imaging to maximally use the radiosynthesis of imaging tracer significantly reduces the cost of PET and results in increased availability of PET tracer use in neuro-oncology.